PRKAA1 and type 2 diabetes mellitus: Recently, more specific direct activators of AMPK have been identified and tested in preclinical studies, and few of them have already entered human clinical trials for type 2 diabetes and cardiovascular diseases (Steinberg and Carling, 2019).